Evidence map›Paper›PMID 37879695›Full record

ArticleBMJ open2023

Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK.

Ravindhi Murphy, Gurvin Chander, Maria Martinez, Caroline Ward, Sairah R Khan, Mitesh Naik, Tara Barwick, Eric Aboagye, Rohini Sharma

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05178693 (The Epigenetic Modification of Somatostatin Receptor-2 to Improve Therapeutic Outcome With Lutathera in Patients With Metastatic Neuroendocrine Tumours.), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05178693 phase1recruitingnot on this map

The Epigenetic Modification of Somatostatin Receptor-2 to Improve Therapeutic Outcome With Lutathera in Patients With Metastatic Neuroendocrine Tumours.

TypeinterventionalSponsorImperial College LondonRan2022 to 2029Enrolled27ConditionsNeuroendocrine TumorsArmsASTX727, Lutathera
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ravindhi MurphyDepartment of Surgery and Cancer, Hammersmith Hospital, London, UK.
Gurvin ChanderDepartment of Surgery and Cancer, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
Maria MartinezDepartment of Surgery and Cancer, Hammersmith Hospital, London, UK.
Caroline WardDepartment of Surgery and Cancer, Imperial College London, London, UK.
Sairah R KhanDepartment of Nuclear Medicine, Hammersmith Hospital, London, UK.
Mitesh NaikDepartment of Nuclear Medicine, Hammersmith Hospital, London, UK.
Tara BarwickDepartment of Cancer and Surgery, Imperial College London, London, UK.
Eric AboagyeDepartment of Surgery and Cancer, Imperial College London, London, UK.
Rohini SharmaDepartment of Surgery and Cancer, Hammersmith Hospital, London, UK r.sharma@imperial.ac.uk.ORCID 0000-0003-2441-549X
Hammersmith Hospital · GBImperial College London · GBBirmingham Women’s and Children’s NHS Foundation Trust · GBImperial College Healthcare NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSuitability for peptide receptor radionuclide therapy (PRRT) for neuroendocrine neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by [68Ga]Ga-DOTA-peptide-positron emission tomography (PET). Some patients have low or no uptake on [68Ga]Ga-DOTA-peptide-PET, precluding PRRT. The upstream promoter region of SSRT2 is methylated, with percentage of methylation correlating with SSTR2 expression. Demethylating agents increase uptake on PET imaging in vivo such that tumours previously negative on PET become positive, correlating with a dose dependent increase in tumorous SSTR2 expression. LANTana will determine whether treatment with the demethylating agent, ASTX727, results in re-expression of SSTR2 using [68Ga]Ga-DOTA-peptide-PET to image epigenetic modification of the SSTR2 locus, allowing subsequent PRRT. METHODS AND ANALYSIS: 27 participants with a histological diagnosis of NEN (Ki67 ETHICS AND DISSEMINATION: LANTana has ethical approval from Leeds West Research Ethics Committee (REC Reference: 21/YH/0247).Sponsored by Imperial College London and funded by Advanced Accelerator Applications pharmaceuticals. Results will be presented at conferences and submitted to peer-reviewed journals for publication and will be available on ClinicalTrials.gov. TRIAL REGISTRATION NUMBERS: EUDRACT number: 2020-003800-15, NCT05178693.

Indexed as

LantanaNeuroendocrine TumorsClinical Trials, Phase I as TopicDecitabineDrug CombinationsHeterocyclic Compounds, 1-RingHumansLeukocytes, MononuclearLutetiumPositron Emission Tomography Computed TomographyQuality of LifeRadioisotopesReceptors, SomatostatinTreatment OutcomeUnited Kingdom1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidDecitabinedecitabine and cedazuridine drug combinationDrug CombinationsHeterocyclic Compounds, 1-RingLutetiumLutetium-177RadioisotopesReceptors, SomatostatinAdult oncologyCLINICAL PHARMACOLOGYHepatobiliary tumoursNUCLEAR MEDICINE

Identifiers

PMID37879695
PMCPMC10603539
OpenAlexW4387940634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.